First UK experience of BTK inhibitor PCI-32765-dramatic responses in relapsed/refractory mantle cell lymphoma

被引：0
|
作者：
Furtado, M. V. [1 ]
Rule, S. [1 ]
机构：
[1] Derriford Hosp, Dept Haematol, Plymouth PL6 8DH, Devon, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
119
引用
收藏
页码：47 / 48
页数：2
相关论文
共 50 条
  • [21] Changes in immune cell populations in relapsed/refractory CLL patients treated with a Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in combination with Bendamustine and Rituximab (BR)
    Damle, Rajendra N.
    Temburni, Sonal
    Aggarwal, Prachi
    O'Brien, Susan
    Barrientos, Jacqueline
    Brown, Jennifer R.
    Flinn, Ian W.
    Barr, Paul
    Burger, Jan
    Friedberg, Jonathan W.
    Rai, Kanti R.
    Chang, Betty
    James, Danelle
    Buggy, Joseph
    Chiorazzi, Nicholas
    CANCER RESEARCH, 2013, 73 (08)
  • [22] Polatuzumab Vedotin As an Effective Salvage Therapy for Relapsed/Refractory Mantle Cell Lymphoma Resistantance to BTK and BCL Inhibitors
    Yang, Ping
    Li, Chunyuan
    Yang, Yuan
    Liu, Shuozi
    Wang, Jing
    Chen, Yingtong
    Zhang, Weilong
    Jing, Hongmei
    BLOOD, 2024, 144 : 6303 - 6303
  • [23] Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
    Villa, Diego
    Jiang, Aixiang
    Visco, Carlo
    Crosbie, Nicola
    Mcculloch, Rory
    Buege, Michael J.
    Kumar, Anita
    Bond, David A.
    Paludo, Jonas
    Maurer, Matthew J.
    Thanarajasingam, Gita
    Lewis, Katharine L.
    Cheah, Chan Y.
    Baech, Joachim
    El-Galaly, Tarec C.
    Kugathasan, Laveniya
    Scott, David W.
    Gerrie, Alina S.
    Lewis, David
    BLOOD ADVANCES, 2023, 7 (16) : 4576 - 4585
  • [24] Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults
    De, Surya K.
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (30) : 4757 - 4762
  • [25] EXPERIENCE OF IBRUTINIB IN RELAPSED/REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA AND MANTLE CELL LYMPHOMA IN A UK DISTRICT GENERAL HOSPITAL
    Lala, J.
    Smith, A.
    Millar, C.
    Fellows, G.
    Bryan, A.
    Addada, J.
    HAEMATOLOGICA, 2017, 102 : 720 - 721
  • [26] Single centre experience of a Bruton's tyrosine kinase (BTK) specific inhibitor (ONO-4059) in relapsed mantle cell lymphoma (MCL)
    Walter, H. S.
    Hutchinson, C. V.
    Sharpe, J.
    Duffy, K.
    Nishimura, A.
    Abe, S.
    Honda, H.
    Yasuhiro, T.
    Yoshizawa, T.
    Birkett, J.
    Courtenay-Luck, N.
    Dyer, M. J. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 58 - 59
  • [27] The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL
    Staudt, Louis M.
    Dunleavy, Kieron
    Buggy, Joseph J.
    Hedrick, Eric
    Lucas, Nicole
    Pittaluga, Stefania
    Jhavar, Sameer
    Schmitz, Roland
    Williams, Mickey
    Lih, Jason
    Jaffe, Elaine S.
    Wilson, Wyndham H.
    BLOOD, 2011, 118 (21) : 1168 - 1169
  • [28] IBRUTINIB EXPERIENCE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA: SINGEL CENTER EXPERIENCE
    Uysal, A.
    Soyer, N. Akad
    Patir, P.
    Duran, M.
    Koseoglu, F. D.
    Sahin, F.
    Vural, F.
    Tombuloglu, M.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S35 - S35
  • [29] Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)
    Soumerai, Jacob D.
    Diefenbach, Catherine S.
    Samaniego, Felipe
    Kumar, Abhijeet
    Tsai, Michaela L.
    Asch, Adam S.
    Jagadeesh, Deepa
    Kenkre, Vaishalee P.
    Lossos, Izidore S.
    Salman, Huda
    Awan, Farrukh T.
    Miao, Lu
    Ghalie, Richard G.
    Zelenetz, Andrew D.
    BLOOD, 2022, 140
  • [30] A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
    Blum, Kristie A.
    Christian, Beth
    Flynn, Joseph M.
    Jaglowski, Samantha M.
    Jones, Jeffrey Alan
    Maddocks, Kami
    Byrd, John C.
    BLOOD, 2012, 120 (21)
12345